NASDAQ
ACADIA Pharmaceuticals Inc. (ACAD) has a consensus Buy rating from 37 analysts with an average price target of $33.67, representing +55.9% upside from the current price of $21.60.
| Date | Analyst | Firm | Target | Price | Upside |
|---|---|---|---|---|---|
| Mar 2, 2026 | Unknown | William Blair | $29.00 | $22.81 | +27.14% |
| Feb 23, 2026 | Rudy Li | Wolfe Research | $33.00 | $24.73 | +33.44% |
| Feb 23, 2026 | Unknown | Mizuho Securities | $35.00 | $23.99 | +45.89% |
| Feb 3, 2026 | Unknown | RBC Capital | $31.00 | $26.13 |
May 8, 2026 | Maintained | Citigroup | Buy | Buy |
Mar 25, 2026 | Upgrade | B of A Securities | Neutral | Buy |
Mar 4, 2026 | Maintained | JP Morgan | Overweight | Overweight |
Feb 26, 2026 | Maintained | Stifel | Hold | Hold |
Feb 26, 2026 | Maintained | TD Cowen | Buy | Buy |
| +18.64% |
| Jan 6, 2026 | Ashwani Verma | UBS | $40.00 | $26.66 | +50.04% |
No price data available for this timeframe.